This company has been marked as potentially delisted and may not be actively trading. IMARA (IMRA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock IMRA vs. MENS, MOR, GMTX, CALT, ZYME, SBTX, MBX, NLTX, CYBN, and BIOAShould you be buying IMARA stock or one of its competitors? The main competitors of IMARA include Jyong Biotech (MENS), MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Neoleukin Therapeutics (NLTX), Cybin (CYBN), and BioAge Labs (BIOA). IMARA vs. Its Competitors Jyong Biotech MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Neoleukin Therapeutics Cybin BioAge Labs IMARA (NASDAQ:IMRA) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical preparations industry companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation. Does the media refer more to IMRA or MENS? In the previous week, Jyong Biotech had 5 more articles in the media than IMARA. MarketBeat recorded 6 mentions for Jyong Biotech and 1 mentions for IMARA. Jyong Biotech's average media sentiment score of 0.31 beat IMARA's score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the news media. Company Overall Sentiment IMARA Neutral Jyong Biotech Neutral Do insiders and institutionals have more ownership in IMRA or MENS? 49.3% of IMARA shares are held by institutional investors. 37.3% of IMARA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is IMRA or MENS more profitable? IMARA's return on equity of 2.12% beat Jyong Biotech's return on equity.Company Net Margins Return on Equity Return on Assets IMARAN/A 2.12% 2.00% Jyong Biotech N/A N/A N/A Which has better valuation and earnings, IMRA or MENS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMARAN/AN/A$1.49M$0.05780.60Jyong BiotechN/AN/AN/AN/AN/A SummaryIMARA beats Jyong Biotech on 4 of the 6 factors compared between the two stocks. Get IMARA News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRA vs. The Competition Export to ExcelMetricIMARAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$822.68M$5.72B$9.77BDividend YieldN/A4.84%3.77%4.10%P/E Ratio780.761.1830.9025.26Price / SalesN/A25.65403.8188.28Price / Cash75.2419.5625.2228.45Price / Book11.356.599.516.00Net Income$1.49M-$4.67M$3.26B$265.34M IMARA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRAIMARAN/A$39.03-0.2%N/AN/A$1.02BN/A780.7641MENSJyong BiotechN/A$40.41-18.5%N/AN/A$3.77BN/A0.0031Gap DownHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsGMTXGemini TherapeuticsN/A$58.59+1.0%N/A+24.9%$2.54BN/A-58.5930CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.5011 of 5 stars$13.02+4.7%$21.43+64.6%+37.0%$907.27M$122.87M-8.68460SBTXSilverback TherapeuticsN/A$16.38-6.4%N/A+9.0%$590.63MN/A-6.7783High Trading VolumeMBXMBX Biosciences2.567 of 5 stars$12.53+11.3%$37.63+200.3%N/A$378.27MN/A-2.7636NLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-41.4%$191.25MN/A-6.5490High Trading VolumeCYBNCybin2.4415 of 5 stars$7.63+5.1%$85.00+1,014.0%N/A$171.26MN/A-1.7450Positive NewsBIOABioAge LabsN/A$4.48+3.2%N/AN/A$155.59M$3.86M0.00N/A Related Companies and Tools Related Companies Jyong Biotech Alternatives MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Silverback Therapeutics Alternatives MBX Biosciences Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives BioAge Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRA) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMARA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMARA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access